OSE Immuno has announced the positive verdict of a futility analysis conducted by the DSMB (Independent Drug Safety Monitoring Board) for its Ph II study in UC (ulcerative colitis) in patients with moderate to severe active disease.

This analysis focused on the first 50 patients to complete the induction phase (10 weeks of treatment), with a total cohort of 150 patients," explains Invest Securities.

' As a reminder, the main results of this trial are expected at the end of the year for the induction phase, with data in the maintenance phase expected in H1 2024. Positive results in UC could re-launch OSE-127 following Servier's decision to surrender rights earlier this year. At the same time, the EMA has granted orphan status to OSE-127 in LAL leukemia', says the research firm.

Following this announcement, Invest Securities confirms its Buy recommendation, with a target price of E8.2.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.